title: Osteosarcoma of the jaw bones.
abstract: Osteosarcoma of the jaw bone is comparatively rare and accounts for about 6.5% of all osteosarcomas. We treated eight cases of osteosarcoma of the jaw bone involving the mandible and maxilla in equal proportions between 1986-1992. The median age was 31 years and male: female ratio was 5:3. Swelling and bony expansion were the most common presentations. Radiologically six patients had lytic lesions, and histopathologically they were osteoblastic (n = 4), chondroblastic (n = 3) and fibroblastic (n = 1). Three patients, two with mandibular and one with maxillary osteosarcoma underwent radical surgery and six courses of cisplatinum-based chemotherapy. All were alive and disease free 24, 30, and 54 months after treatment. Histologically all three were chondroblastic. Five patients had incomplete or palliative treatment. All patients died of progressive or locally recurrent disease within 2 years.
authors.affiliation: Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India.
authors.forename: D C
authors.initials: DC
authors.lastname: Doval
authors.forename: R V
authors.initials: RV
authors.lastname: Kumar
authors.forename: V
authors.initials: V
authors.lastname: Kannan
authors.forename: K S
authors.initials: KS
authors.lastname: Sabitha
authors.forename: S
authors.initials: S
authors.lastname: Misra
authors.forename: M
authors.initials: M
authors.lastname: Vijay Kumar
authors.forename: P
authors.initials: P
authors.lastname: Hegde
authors.forename: P P
authors.initials: PP
authors.lastname: Bapsy
authors.forename: K
authors.initials: K
authors.lastname: Mani
authors.forename: A M
authors.initials: AM
authors.lastname: Shenoy
authors.forename: S V
authors.initials: SV
authors.lastname: Kumarswamy
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002423:Cause of Death; D019902:Chondrocytes / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005347:Fibroblasts / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008339:Mandibular Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D008441:Maxillary Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010006:Osteoblasts / Q000473:pathology; D010014:Osteolysis / Q000000981:diagnostic imaging; D012516:Osteosarcoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D010027:Osteotomy; D010166:Palliative Care; D011859:Radiography; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin